Cellular Mechanisms Underlying the Cardioprotective Role of Allicin on Cardiovascular Diseases

José L Sánchez-Gloria1,2, Abraham S Arellano-Buendía3, Juan G Juárez-Rojas4

  • 1Sección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.

Insights

Allicin, a garlic compound, shows potential for treating cardiovascular diseases (CVDs) by modulating cellular mechanisms. This review explores its therapeutic effects on CVD risk factors.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiology

Background:

  • Cardiovascular diseases (CVDs) involve complex, multifactorial origins affecting blood vessels, heart tissue, and rhythm.
  • Current CVD management relies on multidisciplinary approaches and multiple drugs to control risk factors like dyslipidemia, hypertension, and inflammation.
  • Existing pharmacological treatments for CVDs and their risk factors are limited or not fully established in clinical practice.

Purpose of the Study:

  • To review the cellular mechanisms underlying allicin's therapeutic effects.
  • To evaluate allicin's potential as a therapeutic option for CVD prevention and treatment.
  • To highlight allicin's impact on key cardiovascular risk factors.

Main Methods:

  • Literature review of studies on allicin and cardiovascular health.
  • Analysis of cellular mechanisms and signaling pathways affected by allicin.
  • Synthesis of evidence regarding allicin's effects on cardiovascular risk factors.

Main Results:

  • Allicin, a sulfur compound from garlic, demonstrates beneficial effects on multiple cardiovascular risk factors.
  • Allicin modulates key cellular mechanisms and signaling pathways relevant to CVD.
  • Evidence suggests allicin's role in mitigating dyslipidemia, hypertension, oxidative stress, and inflammation.

Conclusions:

  • Allicin exhibits significant therapeutic potential for cardiovascular diseases and their associated risk factors.
  • Understanding allicin's cellular actions provides a basis for its development as a novel CVD therapeutic agent.
  • Further research is warranted to translate these findings into clinical applications for cardiovascular health.

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
715
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
24
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.1K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
26
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
647